BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical‑stage life sciences company focused on discovery, design and development of precision medicines for cancer and immune system-related disorders, today announced the appointment of Dr. Giulio Draetta, M.D., Ph.D., as Chief Strategy Officer. Dr. Draetta joins Orionis at an exciting phase of growth as the company advances and broadens its portfolio across molecular glues, conditionally active cytokines, immune

Veteran ophthalmology executive with over 30 years of experience spanning R&D, manufacturing, quality, commercial strategy, and franchise leadership Former Vice President and Global Head of Retina at Alcon, with deep experience building and scaling global ophthalmic franchises Appointment strengthens operational leadership as Nanoscope advances MCO-010 (MOGENRY™) toward BLA submission and potential commercialization DALLAS, April 1, 2026 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnolo

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH). The Brilliance Studies program consists of three 12-w

BOSTON--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that the first participant has been dosed in the company’s third Phase 1b study of NTX-1955, designed to evaluate its safety and tolerability in generalized anxiety disorder (GAD). NTX-1955 is Newleos’ GABAA-γ1 positive allosteric modulator (PAM) and represents a potential first-in-class treatment for GAD. The Phase 1b study

DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File (DMF) will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceut

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: “Bruker is delighted that Thierry is joining our Board. I have admired his suc

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company’s financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access

NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2026, informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listi

HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Even trace amounts can compromise biological products, causing adverse reactions and regulatory headaches. Endotoxin-free recombinant proteins are the solution. What Are the Potential Risks of Endotoxin? E